naproxen has been researched along with leuprolide in 3 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (leuprolide) | Trials (leuprolide) | Recent Studies (post-2010) (leuprolide) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 3,082 | 777 | 772 |
| Protein | Taxonomy | naproxen (IC50) | leuprolide (IC50) |
|---|---|---|---|
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | 0.0005 | |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | 0.0006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Oh, TH; Park, SC | 1 |
3 other study(ies) available for naproxen and leuprolide
| Article | Year |
|---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Fever as a first presentation of castration-resistant prostate cancer: A case report.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Leuprolide; Male; Naproxen; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2022 |